Get our Free Patent Expiration, Litigation, and Drug Price Updates

Serving hundreds of leading biopharmaceutical companies globally:

UBS
Fuji
Accenture
Baxter
Cantor Fitzgerald
US Department of Justice

Generated: May 26, 2019

DrugPatentWatch Database Preview

Details for Patent: 7,531,530

« Back to Dashboard

Which drugs does patent 7,531,530 protect, and when does it expire?

Patent 7,531,530 protects RUBRACA and is included in one NDA.

This patent has fifty-seven patent family members in twenty-three countries.

Summary for Patent: 7,531,530
Title:Therapeutic compounds
Abstract: The invention relates to trycyclic lactam indole derivatives and triacyclic lactam benzimodole derivatives and their use in inhibiting the activity of PARP enzyme. The invention also relates to the use of these compounds in the preparation of medicaments.
Inventor(s): Helleday; Thomas (Stockholm, SE), Curtin; Nicola (Tyne and Wear, GB)
Assignee: Cancer Research Technology Limited (London, GB) Pfizer (New York, NY)
Application Number:10/565,308
Prior Art and Litigation SupportOrder Prior Art and Litigation support for Patent 7,531,530
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,531,530

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ➤ Sign Up ➤ Sign Up MAINTENANCE TREATMENT OF RECURRENT EPITHELIAL OVARIAN, FALLOPIAN TUBE OR PRIMARY PERITONEAL CANCER, WHO ARE IN A COMPLETE OR PARTIAL RESPONSE TO PLATINUM-BASED CHEMOTHERAPY ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATING EPITHELIAL OVARIAN, FALLOPIAN TUBE, OR PRIMARY PERITONEAL CANCER, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION ➤ Sign Up
Clovis Oncology Inc RUBRACA rucaparib camsylate TABLET;ORAL 209115-001 Dec 19, 2016 RX Yes No ➤ Sign Up ➤ Sign Up A METHOD FOR TREATING OVARIAN CANCER BY ADMINISTERING RUCAPARIB, WHEREIN THE CANCER IS ASSOCIATED WITH A DELETERIOUS BRCA MUTATION ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate

Subscribe to access the full database, or try a Free Trial

Foreign Priority and PCT Information for Patent: 7,531,530

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
United Kingdom0317466.1Jul 25, 2003
United Kingdom0408524.7Apr 16, 2004
PCT Information
PCT FiledJuly 23, 2004PCT Application Number:PCT/GB2004/003183
PCT Publication Date:February 10, 2005PCT Publication Number: WO2005/012305

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
AstraZeneca
Medtronic
Cipla
Express Scripts
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.